Last-Resort access to ceritinib for ALK-Positive cancer patients
NCT ID NCT05100134
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides access to the drug ceritinib (LDK378) for patients with serious ALK-positive tumors, including non-small cell lung cancer, who have no other treatment options and cannot join a clinical trial. It is designed for individual patients whose doctors request the drug, and only if the potential benefit outweighs the risks. The program is no longer available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC LYMPHOMA KINASE (ALK)- POSITIVE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Direct-to-Tumor chemo blast halt advanced lung cancer?
- Smart patch and app aim to boost lung recovery after cancer surgery
- Targeted drug LDK378 takes aim at rare ROS1-driven lung cancer
- Custom-Made vaccine aims to stop lung cancer recurrence
- Radiation and immunotherapy combo before lung cancer surgery shows promise in early trial
- New study aims to tame cholesterol side effect of lung cancer drug